[1] Jellinger K A. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain:incidence and topographic distribution——a pilot study[J]. Acta Neuropathol, 2003, 106(3):191-201. [2] Jellinger K A. Formation and development of Lewy pathology:a critical update[J]. J Neurol, 2009, 256(Suppl 3):270-279. [3] Rodriguez M, Rodriguez-Sabate C, Morales I, et al. Parkinson's disease as a result of aging[J]. Aging Cell, 2015, 14(3):293-308. [4] Hanson J C, Lippa C F. Lewy body dementia[J]. Int Rev Neurobiol, 2009, 84:215-228. [5] Helferich A M, Ruf W P, Grozdanov V, et al. alpha-synuclein interacts with SOD1 and promotes its oligomerization[J]. Mol Neurodegener, 2015, 10:66. [6] Szunyogh S, Olah J, Szenasi T, et al. Targeting the interface of the pathological complex of alpha-synuclein and TPPP/p25[J]. Biochim Biophys Acta, 2015, 1852(12):2653-2661. [7] Follmer C, Coelho-Cerqueira E, Yatabe-Franco D Y, et al. Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of alpha-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetal-dehyde (DOPAL)[J]. J Biol Chem, 2015, 290(46):27660-27679. [8] Mhyre T R, Boyd J T, Hamill R W, et al. Parkinson's disease[J]. Subcell Biochem, 2012, 65:389-455. [9] Biagioli M, Pinto M, Cesselli D, et al. Unexpected expression of alpha-and beta-globin in mesencephalic dopaminergic neurons and glial cells[J]. Proc Natl Acad Sci U S A, 2009, 106(36):15454-15459. [10] Richter F, Meurers B H, Zhu C, et al. Neurons express hemoglobin alpha-and beta-chains in rat and human brains[J]. J Comp Neurol, 2009, 515(5):538-547. [11] Wilson M T, Reeder B J. Oxygen-binding haem proteins[J]. Exp Physiol, 2008, 93(1):128-132. [12] Gorgun F M, Zhuo M, Singh S, et al. Neuroglobin mitigates mitochondrial impairments induced by acute inhalation of combustion smoke in the mouse brain[J]. Inhal Toxicol, 2014, 26(6):361-369. [13] Kawada N, Kristensen D B, Asahina K, et al. Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells[J]. J Biol Chem, 2001, 276(27):25318-25323. [14] Kawada N. Current situation and future prospect of cytoglobin research[J]. Nihon Rinsho, 2013, 71(5):927-935. [15] Burmester T, Ebner B, Weich B, et al. Cytoglobin:a novel globin type ubiquitously expressed in vertebrate tissues[J]. Mol Biol Evol, 2002, 19(4):416-421. [16] Shephard F, Greville-Heygate O, Marsh O, et al. A mitochondrial location for haemoglobins-dynamic distribution in ageing and Parkinson's disease[J]. Mitochondrion, 2014, 14(1):64-72. [17] Ferrer I, Gomez A, Carmona M, et al. Neuronal hemoglobin is reduced in Alzheimer's disease, argyrophilic grain disease, Parkinson's disease, and dementia with Lewy bodies[J]. J Alzheimers Dis, 2011, 23(3):537-550. [18] Zhang Z X, Roman G C, Hong Z, et al. Parkinson's disease in China:prevalence in Beijing, Xian, and Shanghai[J]. Lancet, 2005, 365(9459):595-597. [19] Meurers B H, Zhu C, Fernagut P O, et al. Low dose rotenone treatment causes selective transcriptional activation of cell death related pathways in dopaminergic neurons in vivo[J]. Neurobiol Dis, 2009, 33(2):182-192. |